The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...

Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Shares of Gilead Sciences (NASDAQ:GILD) reached a session high on Wednesday after the U.S. Food and Drug Administration (FDA) ...

Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...

Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.